Evidence map›Paper›PMID 32522170›Full record

ArticleBMC cancer2020

LGR5 in breast cancer and ductal carcinoma in situ: a diagnostic and prognostic biomarker and a therapeutic target.

Catharina Hagerling, Mark Owyong, Vaishnavi Sitarama, Chih-Yang Wang, Charlene Lin, Renske J E van den Bijgaart, Charlotte D Koopman, Audrey Brenot, Ankitha Nanjaraj, Fredrik Wärnberg and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 88 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 4 countries.

Catharina HagerlingDepartment of Anatomy and the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, 94143-0452, USA. catharina.hagerling@med.lu.se.
Mark OwyongDepartment of Anatomy and the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, 94143-0452, USA.
Vaishnavi SitaramaDepartment of Anatomy and the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, 94143-0452, USA.
Chih-Yang WangDepartment of Anatomy and the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, 94143-0452, USA.
Charlene LinDepartment of Anatomy and the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, 94143-0452, USA.
Renske J E van den BijgaartDepartment of Anatomy and the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, 94143-0452, USA.
Charlotte D KoopmanDepartment of Anatomy and the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, 94143-0452, USA.
Audrey BrenotDepartment of Anatomy and the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, 94143-0452, USA.
Ankitha NanjarajDepartment of Anatomy and the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, 94143-0452, USA.
Fredrik WärnbergDepartment of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Sahlgrenska University Hospital, S413 45, Gothenburg, Sweden.
Karin JirströmDepartment of Clinical Sciences Lund, Division of Oncology and Pathology, Lund University, SE-221 85, Lund, Sweden.
Ophir D KleinDepartment of Orofacial Sciences, University of California, 513 Parnassus Avenue, San Francisco, CA, 94143-0452, USA.
Zena WerbDepartment of Anatomy and the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, 94143-0452, USA.
Vicki PlaksDepartment of Anatomy and the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, 94143-0452, USA. vicki.plaks@ucsf.edu.
UCSF Helen Diller Family Comprehensive Cancer Center · USUniversity of California, San Francisco · USLund University · SERadboud University Nijmegen · NLUniversity of Gothenburg · SE

Funding

Role of Metalloproteinases in Mammary Gland RemodelingR01CA057621 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WERB, ZENA · 1993 to 2017
$9.0M
Harnessing natural stem cell-based strategies for mammalian dental renewalR35DE026602 · NIDCR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KLEIN, OPHIR D · 2016 to 2023
$8.0M
Integrative approach to heterogeneity in breast cancer metastasisU01CA199315 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GOGA, ANDREI, SPELLMAN, PAUL T. · 2016 to 2020
$3.2M
Role of GATA3 in transcriptional pathways suppressing breast cancer metastasisR01CA190851 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WERB, ZENA · 2015 to 2019
$2.0M
(PQC4) Fate of cells disseminating from human breast cancer xenograftsR01CA180039 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WERB, ZENA · 2013 to 2016
$1.3M
California Breast Cancer Research Program 23IB-001Division of Cancer Epidemiology and Genetics, National Cancer Institute CA057621Division of Cancer Epidemiology and Genetics, National Cancer Institute CA180039Division of Cancer Epidemiology and Genetics, National Cancer Institute CA190851Division of Cancer Epidemiology and Genetics, National Cancer Institute CA199315Ministry of Science and Technology, Taiwan MOST104-2917-I-006-002NCI NIH HHS R01 CA057621NCI NIH HHS R01 CA180039NCI NIH HHS R01 CA190851NCI NIH HHS U01 CA199315NIDCR NIH HHS R35 DE026602NIDCR NIH HHS R35_DE026602
6 · The paper itself

Abstract

backgroundNovel biomarkers are required to discern between breast tumors that should be targeted for treatment from those that would never become clinically apparent and/or life threatening for patients. Moreover, therapeutics that specifically target breast cancer (BC) cells with tumor-initiating capacity to prevent recurrence are an unmet need. We investigated the clinical importance of LGR5 in BC and ductal carcinoma in situ (DCIS) to explore LGR5 as a biomarker and a therapeutic target.

methodsWe stained BC (n = 401) and DCIS (n = 119) tissue microarrays with an antibody against LGR5. We examined an LGR5 knockdown ER

resultsLGR5 expression correlated with small tumor size, lower grade, lymph node negativity, and ER-positivity. ER

conclusionLGR5 has distinct roles in ER

Indexed as

AdultAgedAged, 80 and overAnimalsBiomarkers, TumorBreast NeoplasmsCarcinoma, Intraductal, NoninfiltratingCell Line, TumorErb-b2 Receptor Tyrosine KinasesFemaleHeterograftsHumansMiceMiddle AgedPrognosisReal-Time Polymerase Chain ReactionBiomarkers, TumorErb-b2 Receptor Tyrosine KinasesLGR5 protein, humanReceptors, G-Protein-CoupledRNA, NeoplasmBreast cancerDCISEstrogen receptorLGR5Targeted therapy

Identifiers

PMID32522170
PMCPMC7285764
OpenAlexW3033929349

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.